Expression data from glioblastoma tissue
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA413044 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Expression data from PDE1C knockdown glioblastoma short-term cultures
2025-01-24 | E-GEOD-46538 | ExpressionAtlas
Project description:Expression data from glioblastoma surgical specimens
| PRJNA741898 | ENA
Project description:Expression data of HBV infected liver tissue
2025-01-24 | E-GEOD-83148 | ExpressionAtlas
Project description:Expression data from mouse adipose tissue macrophage
2015-07-31 | E-GEOD-53403 | ExpressionAtlas
Project description:Expression data from glioblastoma derived xenograft and original glioblastoma tumors
| PRJNA1172693 | ENA
Project description:Glioblastomas are among the most lethal cancers; however, recent advances in survival have increased the need for better prognostic markers. microRNAs (miRNAs) hold great prognostic potential being deregulated in glioblastomas and highly stable in stored tissue specimens. Moreover, miRNAs control multiple genes representing an additional level of gene regulation possibly more prognostically powerful than a single gene. The aim of the study was to identify a novel miRNA signature with the ability to separate patients into prognostic subgroups. Samples from 40 glioblastoma patients were included retrospectively; patients were comparable on all clinical aspects except overall survival enabling patients to be categorized as short-term or long-term survivors based on median survival. A miRNome screening was employed, and a prognostic profile was developed using leave-one-out cross-validation. We found that expression patterns of miRNAs; particularly the four miRNAs: hsa-miR-107_st, hsa-miR-548x_st, hsa-miR-3125_st and hsa-miR-331-3p_st could determine short- and long-term survival with a predicted accuracy of 78%. Heatmap dendrograms dichotomized glioblastomas into prognostic subgroups with a significant association to survival in univariate (HR 8.50; 95% CI 3.06-23.62; p<0.001) and multivariate analysis (HR 9.84; 95% CI 2.93-33.06; p<0.001). Similar tendency was seen in The Cancer Genome Atlas (TCGA) using a 2-miRNA signature of miR-107 and miR-331 (miR sum score), which were the only miRNAs available in TCGA. In TCGA, patients with O6-methylguanine-DNA-methyltransferase (MGMT) unmethylated tumors and low miR sum score had the shortest survival. Adjusting for age and MGMT status, low miR sum score was associated with a poorer prognosis (HR 0.66; 95% CI 0.45-0.97; p=0.033). A Kyoto Encyclopedia of Genes and Genomes analysis predicted the identified miRNAs to regulate genes involved in cell cycle regulation and survival. In conclusion, the biology of miRNAs is complex, but the identified 4-miRNA expression pattern could comprise promising biomarkers in glioblastoma stratifying patients into short- and long-term survivors.
2017-10-04 | GSE104554 | GEO
Project description:Expression data from mouse tissue Angiotensin II treated for 0,1,3,7days
2015-08-05 | E-GEOD-59437 | ExpressionAtlas
Project description:Expression data from colorectal adenoma tissue
| PRJNA486325 | ENA
Project description:Expression data from murine caecal tissue
| PRJNA562596 | ENA
Project description:The characterization of glioblastoma has provided invaluable data related to this molecularly heterogeneous disease. Recent advances in high-throughput microarrays have received extensive attention and made substantial progress in reconstructing the gene regulatory network of medical biology. Using microarray analysis, significant differences in gene expression between normal and disease tissues have been observed. However, as a result of the underlying shortcomings of microarray technology, such as small sample size, measurement error, and information insufficiency, unveiling this disease mechanism has remained a major challenge to glioblastoma research. Hence, GO, pathway information, network-based approaches and machine learning algorithms have been employed to identify the mechanisms underlying this disease. We identified the differentially expressed genes (DEGs) between 9 glioblastoma samples and 9 normal brain samples.
2017-02-10 | GSE90886 | GEO